2 results
Approved WMORecruiting
Primary objective: to determine the biological activityof Hespecta that is able to induce HPV16 E6-specific T-cell immunity within a proposed dose escalation of 1, 5, 20 or 50 µg/peptide - conjugate in patients treated for HPV16+ OSCC.Secondary…
Approved WMOCompleted
To assess if short antibiotic treatment (3x24 hours) with an anti-pseudomonal carbapenem (imipenem-cilastatin or meropenem) is safe (NON-INFERIOR) with regard to treatment failure in comparison with extended treatment (at least 9x24hours) of high-…